A 42-year-old woman with a 10-year history of type 2 diabetes mellitus and hypertension is admitted with acute myocardial infarction (anterior wall STEMI). After successful primary percutaneous coronary intervention (PCI), she develops cardiogenic shock with a blood pressure of 85/55 mmHg, heart rate 115 bpm, and reduced cardiac output (cardiac index 1.8 L/min/m²). Standard therapies including fluid resuscitation and mechanical ventilation have been initiated. The cardiologist decides to initiate a low-dose dopamine infusion (3–5 μg/kg/min). What is the primary mechanism by which dopamine at this dose improves hemodynamics in cardiogenic shock?

Explanation

## Dose-Dependent Effects of Dopamine Dopamine is a unique catecholamine with **dose-dependent receptor selectivity**. Understanding these tiers is high-yield for NEET PG. ### Dopamine Receptor Activation by Dose | Dose Range | Primary Receptor | Secondary Receptor | Clinical Effect | |------------|------------------|-------------------|------------------| | **1–3 μg/kg/min** (Low) | D₁, D₂ (dopaminergic) | — | Renal/mesenteric vasodilation; diuresis | | **3–5 μg/kg/min** (Low–Moderate) | β₁-adrenergic | D₁/D₂ | **Increased contractility + CO** (minimal α₁) | | **5–10 μg/kg/min** (Moderate) | β₁ + α₁ | — | Inotropic + vasopressor | | **>10 μg/kg/min** (High) | α₁ (dominant) | β₁ | Vasoconstriction; ↑ SVR; ↓ renal perfusion | **Key Point:** At **3–5 μg/kg/min**, dopamine is predominantly a **β₁-agonist**, increasing myocardial contractility and heart rate without excessive peripheral vasoconstriction. This is the "inotropic" dose range. ## Why This Dose in Cardiogenic Shock? **High-Yield:** In cardiogenic shock post-MI, the problem is **low cardiac output** due to myocardial dysfunction. Low-dose dopamine: 1. **Increases contractility** via β₁-receptor activation → ↑ stroke volume and cardiac output 2. **Increases heart rate** slightly (β₁ effect on SA node) 3. **Preserves renal perfusion** (residual D₁-mediated vasodilation) 4. **Avoids excessive vasoconstriction** (α₁ effects are minimal at this dose) **Clinical Pearl:** The goal in cardiogenic shock is to improve cardiac output (CO = HR × SV). Dopamine at 3–5 μg/kg/min achieves this by increasing contractility (SV) without the peripheral vasoconstriction that would increase afterload and worsen ventricular function. ## Comparison: Dopamine vs. Other Inotropes in Cardiogenic Shock | Agent | Mechanism | CO ↑ | SVR | Renal Flow | Use | |-------|-----------|------|-----|-----------|-----| | Dopamine (3–5) | β₁ + D₁ | ↑↑ | ↔ | ↑ | First-line inotrope | | Dobutamine | β₁ > β₂ | ↑↑ | ↓ | ↑ | If SVR already high | | Epinephrine (low) | β₁ > α₁ | ↑↑ | ↑ | ↓ | Refractory shock | | Milrinone | PDE-3 inhibitor | ↑ | ↓ | ↑ | Lusitropic; ↓ afterload | **Mnemonic: "Low-dose Dopamine = Dobutamine-like"** — At 3–5 μg/kg/min, dopamine behaves like dobutamine (inotrope with mild vasodilation), not like high-dose dopamine (vasopressor). ## Monitoring & Titration - Target: Cardiac index >2.2 L/min/m², SBP >90 mmHg, urine output >0.5 mL/kg/hr - If inadequate response, escalate to higher dopamine dose or add vasopressor (norepinephrine) - Watch for tachycardia and arrhythmias (β₁ side effects) [cite:Harrison 21e Ch 297; KD Tripathi 8e Ch 11]